MannKind Corporation (MNKD), a small cap biotechnology in Valencia, California, planted the catalytic seeds for revolutionary diabetes treatment more than a decade ago that are now materializing for aggressive growth. In this research report, the author will provide a comprehensive analysis of MNKD through his unique views as a practicing MD, researcher, and investor.
Revolution in Diabetes Mellitus Treatments
The market for diabetes mellitus is increasingly gigantic. Research estimates that over 25 million or 8.3% of the U.S. population have diabetes mellitus in 2011. There are 1.9 million new cases each year. Overweight and obesity are quite common in the U.S. as well as modernizing nations. Being overweight leads to obesity; Obesity leads...
Only subscribers can access this article, which is part of the PRO research library covering 3,573 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: